AbbVie Reports First-Quarter 2023 Financial Results

Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent; These...

Related Keywords

United States ,American ,Richarda Gonzalez ,Lumigan Ganfort ,Linzess Constella ,Alphagan Combigan ,Abbvie Inc ,Drug Administration ,Colitis Organisation ,Exchange Commission ,Capsida Biotherapeutics Inc ,American Academy Of Dermatology ,Twitter ,European Union ,Janssen Biotech Inc ,European Commission ,Allergan ,Boehringer Ingelheim ,Reports First Quarter Diluted ,Adjusted Diluted ,These Results Include ,Unfavorable Impact ,Milestones Expense ,First Quarter Net Revenues ,Reported Basis ,Quarter Global Net Revenues ,Immunology Portfolio Were ,Operational Basis ,Global Humira Net Revenues Were ,Global Skyrizi Net Revenues Were ,Global Rinvoq Net Revenues Were ,Hematologic Oncology Portfolio Were ,Global Imbruvica Net Revenues Were ,Global Venclexta Net Revenues Were ,Neuroscience Portfolio Were ,Global Botox Therapeutic Net Revenues Were ,Global Vraylar Net Revenues Were ,Aesthetics Portfolio Were ,Global Botox Cosmetic Net Revenues Were ,Global Juvederm Net Revenues Were ,Share Related ,Milestones Expense Incurred During ,First Quarter ,Botox Therapeutic ,Botox Cosmetic ,Janus Kinase ,Tyrosine Kinase ,European Crohn ,Annual Meeting ,Janssen Biotech ,Complete Response Letter ,New Drug Application ,Allergan Aesthetics ,Investor Relations ,Private Securities Litigation Reform Act ,Quarterly Reports ,Ended March ,Abbvie ,